Overview
- 35 inspections across 34 sites are on record.
- 85 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2026-02-18.
At a glance
Inspections
35
Sites
34
Observations
85
Career since
Feb 2008
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| Gilead Sciences, Inc. | 18 Feb 2026 | Human Drugs | On file |
| Sparsha Pharma Usa Inc | 4 Sep 2025 | Human Drugs | On file |
| Surmasis Pharmaceutical, LLC | 1 Aug 2025 | Human Drugs | View 483 → |
| Bachem Americas, Inc. | 25 Oct 2024 | Animal Drugs & Feeds | On file |
| Laboratoires Clarins | 14 Oct 2022 | Human Drugs | On file |
Sites inspected
Gilead Sciences, Inc.La Verne, United States1 insp.
Sparsha Pharma Usa IncOceanside, United States1 insp.
Surmasis Pharmaceutical, LLCDes Moines, United States1 insp.
Bachem Americas, Inc.Torrance, United States1 insp.
Laboratoires ClarinsPontoise, France1 insp.
Co-investigators
Investigators who share inspections with this person.
Cassandra L Abellard3 shared
Sixto M Mercado Rios3 shared
Kim L Thomas Cruse3 shared
Pearl C Ozuruigbo2 shared
Cecilia H Kieu2 shared
Uttaniti Limchumroon2 shared
Xiaokuang Lai2 shared
Richard A Lyght2 shared
Brian J Ryan2 shared
Brian P Putz2 shared
Full investigator report
Get the verbatim findings behind Katherine E Jacobitz's 85 observations
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site